publish
compani report initi coverag
total return target
halifax-bas
compani
lead candid dpx-survivac evalu
clinic collabor merck
immunotherapi base
initi coverag imv inc outperform rate per
share target price high risk/specul suitabl given imv current stage clinic
develop view imv compani potenti pioneer new class
immunotherapi capabl reprogram immun cell vivo view
imv data gener date around dpx-survivac highli encourag potenti
support number fast market strategi broad oncolog applic
strong earli line posit therapeut regimen
dpx repres novel approach immunotherapi dpx lipid nanoparticl
deliveri platform releas mechan action moa moa result
activ uptak vivo deliveri activ excipi immun cell
lymph node imv believ leverag program gener new
type cell therapeut capabl bypass convent immun respons
associ limit imv lead dpx formul target survivin
protein ubiquit express across multipl tumor type turn enabl
redirect survivin specif cell infiltr
compel anti-tumor activ dpx-survivac combin epocadostat
low dose cyclophosphamid suggest dpx-survivac monotherapi may prove
superior checkpoint inhibitor orr epocadostat activ
recurr ovarian cancer specif combin associ bor
pr sd orr overal dcr recent imv
identifi subpopul
like respond dpx-survivac therapi
support use monotherapi recurr ovarian cancer
multipl clinic read-out imv expect disclos top line data phase
ib/ii trial dpx-survivac combin epocadostat mg decemb
esmo-io compani also identifi subpopul patient
like respond dpx-survivac monotherapi preliminari phase ii result
dpx-survivac monotherapi ovarian cancer expect top line
result dpx-survivac combin pembrolizumab ovarian cancer
dlbcl expect preliminari result phase ii trial dpx-survivac
combin pembrolizumab basket cohort expect top line
result follow
per share target base probabl adjust net present valu
sum part analysi specif model attribut per share valu
imv lead clinic asset dpx-survivac recurr survivin express ovarian cancer
addit deriv per share valu dpx-survivac applic
survivin express dlbcl valuat recommend section detail
pleas read domest foreign disclosure/risk inform begin page analyst certif page
canada research page
tabl content
canada research page
canada research page
imv foundat technolog depovax enabl novel approach deliv activ ingredi
immun system depovax liposome-in-oil deliveri technolog reli no-
releas mechan action forc activ uptak antigen present cell imv util
uniqu mechan action gener new type artifici cell flow blood
trigger kill cancer imv lead clinic candid dpx-survivac encapsul survivin
base peptid licens merck survivin protein member inhibitor apoptosi
protein famili import role regul cell respons anti-tumor immun
ubiquit express number oncolog indic dpx-survivac current
evalu four broad clinic trial mono- combin therapi recurr
ovarian cancer dlbcl basket cohort survivin express tumor
imv present data on-going phase trial evalu dpx-survivac
combin epocadostat low dose cyclophosphamid combin associ
bor pr sd orr overal dcr total evalu cohort
impress recent updat imv disclos strong indic
durabl report one particular respond progress beyond two year mark
without diseas progress result deriv limit sampl size view
observ anti-tumor activ highli encourag even industri lead particularli
light avelumab recent phase miss ovarian cancer drug associ
orr monotherapi pembrolizumab all-com trial result indic orr
max durat respons month recent compani report
identif subpopul like benefit treatment dpx-survivac
compani intend evalu popul util dpx-survivac monotherapi
without epocadostat fail exhibit anti-tumor activ
imv guid multipl clinic read-out believ could repres signific
valu creation event compani specif expect compani disclos
preliminari data phase trial evalu dpx-survivac monotherapi ovarian
cancer addit phase result evalu dpx-survivac combin pembrolizumab
dlbcl ovarian cancer within anticip preliminari result phase
trial evalu dpx-survivac combin pembrolizumab basket cohort
follow top line result final anticip clariti around regulatori strategi
support fast-to-market approach aforement indic
imv lead clinic candid dpx-survivac current evalu monotherapi
combin therapeut ovarian cancer dlbcl basket cohort
survivin express tumor believ appropri valuat methodolog
captur inher valu imv multipl clinic endeavor probabl adjust
net present valu sum part analysi evalu dpx-survivac recurr ovarian
cancer assum util line therapi model sale us
eu probabl adjust ovarian cancer valuat result per share valu
respect dpx-survivac dlbcl model util line therapi
account sale us eu probabl adjust dlbcl valuat
result per share valu aggreg sotp valuat methodolog result
per share target imv
canada research page
headquart halifax scotia imv inc clinic stage biotechnolog compani
develop novel class immunotherapi enabl proprietari lipid depot-bas deliveri
technolog depovax util depovax deliveri platform compani gener data
demonstr abl induc strong durabl immun respons believ
signific applic multipl oncolog infecti diseas indic well
potenti therapeut area date compani underli technolog garner
interest number commerci partner includ merck zoeti leido
imv partnership result number depovax formul specif clinic
compani lead clinic candid dpx-survivac current evalu co-fund
phase ib trial investig combin dpx-survivac oral
indoleamin inhibitor epacadostat ovarian cancer patient
addit dpx-survivac evalu two investigator-sponsor phase ii clinic trial
combin merck select human monoclon antibodi known
pembrolizumab target program cell death receptor lymphocyt
patient recurr platinum-resist ovarian cancer patient measur
recurr diffus larg cell lymphoma final compani also evalu depovax
human
papillomaviru hpv relat cancer beyond oncolog imv complet proof concept
phase studi util depovax base formul target respiratori syncyti viru rsv
present review imv clinic pipelin exhibit
collabor dana-farb cancer
institut use
background imv reach far annal histori far back
dalhousi univers dr kimmin dr robert brown et al contract depart
fisheri ocean develop contracept vaccin control grow seal popul
threaten fisheri support economi atlant canada coastal
water time contracept vaccin primarili aqueou base solut
requir prime shot booster abl achiev contracept approxim
time howev would requir re-vaccin everi year simpli practic
particular use case dr brown et al opt develop oil-bas emuls protect
canada research page
antigen thu enabl far durabl stimul immun system result effect
contracept less half time higher level contracept durat
effect approach aqueou solut singl dose identifi broader
applic technolog dr kimmin dr brown spun ip underli
technolog form immunovaccin technolog inc march
immunovaccin focus effort anim contracept wildlif
companion anim also work vaccin infecti diseas livestock
anim health subsequ acquir anim health divis
later spun zoeti
continu immunovaccin began establish technolog
brand vaccimax platform variou human applic simultan
establish scalabl manufactur process immunovaccin develop lipid
depot-bas vaccin deliveri enhanc technolog brand depovax
platform improv foundat vaccimax platform octob
depovax establish compani began trade tsxv name immunovaccin
inc ipo price per share
immunovaccin enter agreement merck in-licens survivin antigen
use tradit vaccin deliveri technolog merck unabl gener suffici
immunogen antigen justifi develop reformul survivin
antigen deliveri platform immunovaccin observ preclin research late-stag
human cancer could target thu immunovaccin first clinic candid dpx-survivac
emerg howev despit success earli day immunovaccin public compani
view limit lack focu compani pursu number endeavor
attempt find stride develop depovax multipl preclin studi util antigen
pandem influenza hepat melioidosi cocain anthrax ebola viru
oper compani appear scatter consist observ began drawn
across program specif antigen administ util depovax result
significantli higher immun respons singl dose rel two three dose control
follow period limit progress compani ripe refresh april
immunovaccin appoint mr fred or act ceo compani posit
cement one year later april ultim mr or join former colleagu
medicago acquir mitsubushi pharma mln mr andi sheldon mr
pierr labb view old medicago team helm immunovaccin clarifi
strategi focus effort firmli elucid depovax novel mechan action moa
leverag dpx-survivac abil activ direct cell respons multipl clinic
develop program newli articul oper clariti compani chang
name imv inc may concurr list better reflect busi
compani evolv well beyond develop vaccin compani
develop novel immuno-therapeut
enhanc potenc peptid vaccin imv develop novel vaccin platform call
depovax liposome-in-oil platform contain stabl compon requir creation
emuls simplifi use oil-bas depot vaccin clinic formul
peptid antigen dpx formul result robust persist cell immun
respons dpx may also includ adjuv help initi direct immun respons
prepar dpx formul antigen adjuv encapsul liposom
lyophil result cake reconstitut directli oil montanid vg prior
inject presenc lipid ensur compon formul
suspend oil
canada research page
non-aqu lipid nanoparticl suspens result dpx releas mechan
action specif
entrap protect activ ingredi degrad prevent off-target
forc activ uptak target transport deliveri lymph node immun
leverag specif target program immun cell cell cell
gener new therapeut capabl bypass convent immun respons
inher limit
afford potenti co-deliv multipl ingredi togeth program immun
date dpx dose patient technolog easili manufactur fulli
synthet deliv hydrophil hydrophob compound wide rang
applic deliveri peptid small-molecul nucleotid antibodi highli
stabl particularli lyophil format rel cheap produc
dpx platform provid novel way deliv activ ingredi immun system
discuss reli releas mechan action forc activ uptak
antigen present cell dpx substanti differenti cancer vaccin
gener cancer vaccin tend short peak respons fail result durabl
tumor regress short peak respons simpli unabl trigger efficaci
durabl tumor respons contrast dpx bypass immun system limit
directli gener new type artifici cell flow blood trigger kill
cancer sustain long period time repeat inject everi month
dpx shown induc prolong target-specif polyfunct cell respons
believ requir effect tumor control demonstr intens
durat cell flow induc cancer vaccin vs imv dpx technolog exhibit
canada research page
imv endeavor leverag mechan action pioneer new class immuno-
therapeut specif prevent releas activ ingredi site inject
dpx abl bypass step involv convent immun nativ respons
vaccin enabl access reprogram immun cell vivo gener new
synthet therapeut capabl specif imv believ novel mechan action
dpx make platform particularli suitabl cancer immunotherapi design
compani lead clinic candid dpx-survivac util survivin-bas peptid licens
merck juli world-wid basi formul dpx compani current
investig dpx-survivac four broad clinic trial follow
phase trial ovarian cancer tripl combin dpx-survivac
oral cyclophosphamid mcpa epacadostat mg recent
amend progress dpx-survivac mcpa monotherapi
canada research page
phase trial ovarian cancer merck tripl combin dpx-survivac oral
phase trial diffus larg b-cell lymphoma dlbcl merck tripl combin
dpx-survivac oral cyclophosphamid mcpa pembrolizumab
phase basket trial includ bladder liver ovarian non-smal cell lung
microsatellit instabl high msi-h cancer tripl combin dpx-survivac
present illustr review imv immuno-oncolog pipelin exhibit
cancer one widespread preval class indic global heterogen
group diseas normal cell either spontan somat germlin mutat
begin grow abnorm escap control mechan lose contact inhibit sever case
gain potenti metastas spread bodi part accord global cancer
fact figur edit predict global burden expect grow
million new cancer case million cancer death simpli due growth age
global popul needless say cancer fatal appropri treat time
manner current standard care includ surgeri chemotherapi radiotherapi
significantli improv prognosi howev drug resist metastat spread diseas
remain signific challeng median surviv rate mani cancer type remain poor
recent substanti clinic data indic immunotherapi serv power
therapeut tool prevent metastat spread cancer accord market market report
releas januari global immunotherapi drug market project reach
bln bln grow compound-annual-growth-rate forecast period
today major player immunotherapi market includ astrazeneca
bm eli lilli gsk merck novarti roch number smaller develop stage
biopharmaceut compani number current coverag raymond
fundament thesi behind immunotherapi cancer natur best thu
efficaci killer one immun system thu
substanti invest drive effort har immun system identifi treat
prevent tumor recurr date number
immuno-oncolog therapeut
demonstr abil prolong patient surviv clinic success
turn elucid underli immun dysfunct characterist cancer
broadli speak immunotherapi broken distinct subgroup monoclon
canada research page
bcg etc checkpoint inhibitor vaccin oncolyt antigen whole cell dendrit cell
dna anti-idiotyp vaccin etc adopt cell transfer therapi
respect checkpoint inhibitor yervoy ipilumumab develop bm
first compound class approv use advanc metastat melanoma
cancer regul ligand act inhibit cell mediat anti-
tumor immun respons crucial tumor control monoclon antibodi target
shown impress efficaci cancer patient signific percentag
patient experienc durabl respons therapi sever compound
advanc clinic trial one compound merck keytruda pembrolizumab receiv
fda approv septemb advanc melanoma patient stop respond
therapi bm compound nivolumab opdivo also approv unit
state japan therapi recent approv use advanc cancer
carcinoma head neck stomach cancer addit keytruda particular
approv use cancer specif molecular indic irrelev cancer type
approv may use treat solid tumor biomark microsatellit
instabl msi-h defect dna repair pathway repres
number differ tumor type includ colorect breast prostat thyroid cancer
howev despit recent clinic success induct enhanc anti-tumor respons
formid challeng cancer tumor cell use multipl evas strategi allow
avoid detect associ elimin immun cell
order combat evas mechan research suggest combin strategi
checkpoint inhibitor like good therapeut option drive tumor specif
immun respons includ novel cancer vaccin cell base therapi
therapi fit well checkpoint inhibit therapi simultan activ strong
tumor specif immun respons releas brake immun suppress
success combin allow pharmaceut compani significantli expand
market checkpoint inhibitor current effect approxim
patient imv believ cell therapi becom import compon novel
combin immunotherapi potenti induc synergist benefit like
becom essenti part multi-prong approach treatment cancer
resist apoptosi cell death one import evas mechan tumor cell
escap detect immun cell promot prolifer time therefor
molecul involv regul apoptosi potenti target tumor therapi includ
immunotherapi one key group protein inhibitor apoptosi protein famili iap
critic involv regul apoptosi iap also import role regul
cell respons anti-tumor immun one member protein famili survivin
particularli interest due overexpress multipl tumor type see exhibit
canada research page
exhibit ubiquit express survivin
short survivin span kb telomer end chromosom encod
kd protein encompass amino acid survivin dual function play
role cell death regul mitot progress illustr exhibit
research suggest express survivin alter cancer certain chang
may directli implic carcinogen process due role cancer gene
intersect multipl cellular network survivin vigor use cancer drug target
compar apoptosis-bas cancer therapi survivin provid sever
cancer express lung myeloid lymphocyt canada research page
advantag first disabl survivin expect compromis multipl signal network
requir tumor mainten second survivin may uniqu target molecular
antagonist cancer vaccin gene therapi third express survivin regul
wnt signal pathway major role stem cell possibl survivin
formation/progress especi angiogenesi survivin inhibitor shown act
transform popul endotheli cell tumor fifth although survivin
express shown cytokin stimul haematopoiet progenitor activ
cell target pathway affect normal cell tissu suggest favour
toxic profil survivin base therapeut survivin-direct immunotherapi
foundat link four clinic trial discuss
dpx-survivac grant orphan drug design use ovarian cancer ema
fast track design fda use patient measur diseas initi
surgeri chemotherapi june imv announc enter non-exclus
clinic trial collabor evalu combin
imv dpx-survivac novel cell activ therapi contain mix hla class
peptid design evok cell respons survivin
dose cyclophosphamid oral anti-tumor alkyl chemotherapeut use
immun modul
incyt investig oral inhibitor epacadostat select oral inhibitor
present review imv dpx-survivac tripl combin exhibit
chen mellman immun
imv co-fund conduct multicent non-random open-label
uncontrol phase studi name decid trial evalu safeti toler
efficaci novel combin platinum resist sensit ovarian cancer patient
high risk recurr
canada research page
patient enrol trial recurr ovarian cancer evid progress
diseas ind studi test tripl combin dpx-
survivac two dose epacadostat mg mg low dose oral cyclophosphamid
approv us fda health canada januari studi initi
septemb investig complet enrol total patient
across two dose group announc compani august
april imv announc enter agreement incyt corpor
expand on-going clinic trial collabor imv report plan add
phase compon on-going phase combin studi evalu safeti
efficaci dxp-survivac combin epacadostat low dose cyclophosphamid
advanc ovarian cancer patient origin plan phase multicent
random open label efficaci studi would includ addit evalu subject
expect evalu dpx-survivac low dose cyclophosphamid without
epacadostat patient advanc recurr ovarian cancer goal part
program evalu clinic contribut investig drug combin
regimen phase arm studi cofound imv august
imv announc first patient treat howev novemb
imv announc intent proceed dpx-survivac monotherapi without
march imv announc first interim data analysi clinic studi
analysi includ result blood test tumor biopsi ct scan assess safeti diseas
progress cell respons first four evalu patient trial base
interim analysi combin therapi appear well toler treatment
associ singl grade singl grade event seriou advers event sae
time interim analysi patient exhibit stabl diseas sd fourth patient
progress pd exit trial notabl imv observ increas cell activ tumor
three four patient base rna sequenc also report indic earli tumor
shrinkag patient trial longest durat time analysi
base ct scan day
decemb imv provid posit top-lin clinic data initi result evalu
patient dpx-survivac mg epacadostat cohort demonstr diseas control rate
dcr includ best overal respons bor pr combin also
exhibit well-toler safeti profil major report grade grade
blood test indic major treat patient exhibit target cell activ
tumour biopsi analys thu far support thesi combin dpx-
survivac trigger cell infiltr tumor cell activ also correl
tumor regress time data cut-off also preliminari data first three
evalu patient second dose cohort evalu combin mg bid
epacadostat dpx-survivac low-dos cyclophosphamid first three evalu
patient imv report sd one two patient show tumor regress
approxim per cent miss threshold pr
imv provid recent updat clinic trial time data
cut-off patient enrol includ new particip mg cohort
evalu day first ct scan two longer trial data cut-off
total patient current epitheli ovarian cancer fallopian tube periton cancer
receiv singl dose treatment evalu safeti epocadostat
mg group epocadostat mg group patient baselin characterist gener
well match heavili pretreat median prior system regimen
mg epocadostat group prior regimen mg epacadostat cohort
canada research page
treatment tripl combin well toler major
report grade grade
data evalu patient data cut-off date march across
dose cohort demonstr bor tumor regress pr look
specif evalu particip mg epacadostat cohort remain studi
data cut-off date bor includ pr sd dcr pr
group record tumor regress on-going month provid earli
evid long durabl respons
canada research page
exhibit percent chang baselin lesion
imv plan report updat result patient other enrol trial data
least evalu particip second dose cohort avail view
data clearli still preliminari view context ovarian cancer
target immunotherapi trial imv result outperform heavili pretreat
updat imv inc
addit object tumor respons imv also analyz patient data studi
combin moa blood sampl tumor biopsi evalu patient treat
first dose cohort analyz data demonstr
survivin-specif cell respons detect patient
increas cell infiltr post treatment analyz tumor
biopsi base two complementari test methodolog rna sequenc
immunohistochemistri demonstr treatment dpx-survivac inde
increas cell infiltr tumor
patient cell infiltr show pr signific durabl tumor
regress last one year
third patient cell infiltr exhibit pd evid regul
major histocompat present pathway signific increas
suppress marker indic mechan resist
ovarian cancer io clinic trialtrial phase pt dcr orrcheckpoint immunotherapyipilumab-bm pr pr epacadostat-incyt ca sd cr pr nivolumab-bm cr pr cr pr avelumab-merck pr pr pr checkpoint parpidurvalumab-az olaparib parpi pi/ii pr pr pembrolizumab niraparib parpi cr pr cr pr combin immunotherapyepacadostat pembrolizumab sd pr epacadostat nivolumabpi/ii sd pr epacadostat nivolumabpi/ii sd pr pr mcpa epacadostat pib pr pr dpx-survivac mcpa epacadostat pib pr pr averag dpx-survivac mcpa epacadostatpib pr addit patient sd longer studi data cut-off canada research page
novemb imv announc follow post hoc analysi data phase
portion clinic trial dpx-survivac combin cyclophosphamid
epocadostat compani identifi subpopul patient stratifi clinic
marker predict respons dpx-survivac appear benefit treatment
specif subpopul patient mg epocadostat arm
patient experienc tumor regress dcr observ bor group
pr orr admit analysi limit two factor specif
post-hoc analysi data sampl size limit particularli
impress durat respons report compani respond group
median durat day report includ one patient progress beyond
concurr subgroup analysi imv report base result mg
epocadostat arm compani agre stop dose patient epocadostat
date fail demonstr tangibl activ recurr ovarian cancer imv
continu phase trial monotherapi low dose cyclophosphamid
condit regimen evalu dpx-survivac
recurr ovarian cancer
imv anticip meet us fda decemb present subgroup analysi
hope clarifi path registr trial monotherapi recurr ovarian
cancer furthermor imv present detail result analysi decemb
esmo immuno oncolog confer held decemb geneva switzerland
februari imv announc investigator-sponsor phase clinic trial ovarian
cancer combin merck checkpoint inhibitor pembrolizumab patient
network princess margaret cancer centr conduct phase non-random open-label
trial design evalu potenti anti-tumor activ combin
pembrolizumab dpx-survivac low-dos cyclophosphamid
trial expect enrol subject advanc epitheli ovarian fallopian tube
primari periton cancer studi primari object assess overal respons rate
secondari object includ progress free surviv rate overal surviv rate potenti
side effect five-year period imv expect disclos top line result
canada research page
novemb imv announc health canada grant sunnybrook research
institut regulatori clearanc begin recruit patient phase clinic studi triple-
combin immunotherapi patient measur recurr diffus larg b-cell
lymphoma indic survivin express approxim case trial
announc initi may design evalu safeti efficaci
imv lead product candid dpx-survivac along merck pembrolizumab low-dos
trial non-random open label studi expect enrol evalu particip
five center canada septemb imv announc preliminari data
clinic trial preliminari data includ assess safeti clinic activ base
modifi cheson criteria first four evalu patient complet first ct
scan start treatment data demonstr
first four evalu particip show tumor regress first on-
first enrol particip demonstr tumor regress first on-
second particip demonstr partial respons pr via tumor regress
first on-treat scan
preliminari data third particip demonstr stabl diseas
particip earli diseas progress less two month follow
treatment initi discontinu studi
combin therapi appear demonstr accept safeti profil
seriou advers event report date
imv expect disclos top-lin trial
septemb imv announc expans immuno-oncolog develop
pipelin plan phase basket trial collabor merck evalu lead
candid dpx-survivac combin low dose cyclophosphamid merck
therapi pembrolizumab patient select advanc recurr solid tumor
open-label multicent phase basket studi evalu safeti efficaci
immunotherapeut combin agent patient bladder liver ovarian non-smal cell
lung cancer well tumor shown posit microsatellit instabl high msi-h
biomark imv plan enrol patient across five indic multipl medic
center canada unit state imv expect initi trial enrol quarter
preliminari result expect first half follow novemb
announc detail identif biomark predict respons dpx-
survivac compani suggest biomark use prospect select
ovarian cancer patient basket trial
collabor commerci academ partner imv expand applic
depovax deliveri platform compani pursu number endeavor
believ dpx platform may applic gener stronger durabl immun
activ review program
canada research page
april imv announc first studi particip treat phase
clinic studi evalu imv investig cancer vaccin combin
low-dos cyclophosphamid patient incur oropharyng cervic anal cancer
relat hpv dana-farb lead studi million research grant
stand cancer farrah fawcett foundat clinic evalu collabor
translat research address critic problem hpv-relat cancer
dana-farb studi singl center open label non-random clinic trial
investig safeti clinic efficaci combin low-dos metronom
oral cyclophosphamid total treat particip primari object evalu
chang cell peripher blood tumor tissu evalu safeti
vaccin posit patient incur hpv-relat head neck cervic anal
target hpv viral protein known imv option produc
vaccin prove success clinic trial formal guidanc provid
respect top line result
imv complet pre-clin work vaccin target rsv second lead
caus respiratori ill infant elderli immunosuppress current
vaccin avail rsv imv seek develop novel vaccin formul use
elderli healthi adult includ women child-bear age
imv in-licens rsv antigen exclus vib non-profit life scienc research
institut fund flemish govern expand pipelin vaccin candid
novel rsv antigen evalu dpx base short hydrophob protein present
low level surfac rsv virion importantli also present surfac
rsv infect cell vaccin uniqu moa result antibodi bind
destroy infect cell rather directli bind neutral free viru
phase clinic studi conduct canada imv rsv vaccin healthi adult
rsv vaccin formul imv proprietari dpx platform initi develop
protect elderli popul infect phase studi first clinic
trial dpx-base vaccin infecti diseas indic evalu safeti
immun respons profil rsv vaccin candid healthi older adult volunt age
year two dose cohort subject cohort
juli imv announc posit interim result trial compani analyz
safeti immun respons data particip studi day safeti analysi
indic dpx-rsv well toler among studi particip sae record
furthermor immunogen data support dpx-rsv abil gener relev immun
respons vaccin candid obtain antigen-specif antibodi respons subject
vaccin lower dose vaccin higher dose posit top
line data disclos octob compani disclos nine
month follow last vaccin particip receiv dpx-rsv
demonstr antigen-specif immun respons vaccin candid also continu
posit safeti profil well toler sae among studi particip
april imv announc addit posit data extend evalu
patient trial amend submit health canada test subject
receiv higher dose vaccin one year booster vaccin
dose cohort dose test one year older adult immun
respond vaccin dpx-rsv maintain antigen-specif immun respons one
year receiv booster dose one year antibodi level measur still
peak sign decreas
septemb imv announc result on-going research explor novel
moa vaccin candid new data preclin studi highlight effect two
potenti approach prevent rsv compar singl dose bovin version dpx-rsv
antigen-specif immun respons protect effect diseas patholog degre
canada research page
protect compar two vaccin candid studi compani
compar effect imv convent rsv vaccin approach among bovin
known rsv infect bovin anim model consid optim model rsv
infect one dose dpx-brsv administ one cohort second receiv two dose
subunit rsv bovin vaccin immun respons evalu antibodi titer test
diseas patholog assess lung lesion score clinic paramet
bodi temperatur chang imv found sh antibodi subject receiv dpx-
brsv improv observ diseas patholog compar two
cohort first bovin anim health data directli correl vaccine-induc
immun respons imv novel rsv target sh viral protein measur diseas
convent rsv vaccin candid target either protein viru provid
protect neutral rsv viru clinic measur efficaci focu amount
neutral antibodi bloodstream dpx-rsv work differ target sh viral
ectodomain rsv viru instead neutral viru enabl immun system
recogn destroy infect cell sinc neutral antibodi result
dpx-rsv moa differ clinic assess requir determin vaccin candid
protect effect imv exclus world-wide licens applic target sh
ectodomain antigen rsv compani intend explor opportun out-licens
product potenti partner
imv award subcontract leido health nation secur infrastructur
solut compani evalu imv dpx platform develop peptide-bas malaria
vaccin target subcontract fund leido prime contract us agenc
intern develop usaid provid vaccin evalu preclin clinic
field stage malaria vaccin develop novemb expans
collabor announc follow achiev sever preclin mileston
collabor usaid leido usaid select dpx-base platform one
prefer formul develop new contract extens new
subcontract collabor conduct addit research focus identifi
promis target-formul combin
august corpor announc achiev sever mileston on-going
collabor global anim health compani zoeti develop cattl vaccin recent
control studi imv formul met efficaci durat immun end-point
two diseas target result enabl zoeti advanc two imv-formul
vaccin candid late-stag test
ovarian cancer fifth common caus cancer-rel death women surpass
gynecolog cancer us alon estim new case ovarian
cancer diagnos estim women succumb diseas
time frame europ estim number new ovarian cancer case estim
annual global ovarian cancer incid estim new case
woman lifetim risk develop ovarian cancer approxim chanc
die diseas approxim typic diseas present late stage
rel surviv rate case approxim
diagnos local tumor stage surviv rate strikingli
overal rel surviv rate gener rang across globe
seen modest increas sinc despit advanc therapeut option
canada research page
initi treatment option epitheli ovarian cancer includ cytoreduct surgeri follow
platinum taxan chemotherapi neoadjuv chemotherapi follow interv debulk
surgeri due late stage time diagnosi treatment option patient
develop resist frontlin therapi prognosi ovarian cancer poor signific
unmet medic need fuel uptak novel therapeut avenu parp
inhibitor inhibitor angiogenesi inhibitor aggreg expect reach
sale approxim bln
order deriv sale estim dpx-survivac ovarian cancer take conserv
approach assum dpx-survivac approv follow-on treatment
line survivin express recurr ovarian cancer furthermor present model
commerci sale us eu leav approxim address popul
addit ovarian cancer patient rest world
us assum annual ovarian cancer incid detail grow
y/i assum patient recurr follow neoadjuv therapi surgic
intervent recurr ovarian cancer patient assum express survivin
conserv estim dpx-survivac five peptid combin provid
coverag across popul addit net patient popul
harbor high-grad serou tumor relat mutat median
assum respons rate first line adjuv therapi thu assum patient
progress line furthermor assum line patient progress line
line patient progress line treatment
assum product launch penetr assumpt increasingli aggress
respect line start
penetr seven year post launch plateau
line
line model sale assum net launch price per patient year
dpx-survivac irrespect treatment durat substanti discount annual cycl
line
line
line
eu assum higher annual ovarian cancer incid detail
assum discount price per patient year penetr rate
us market assumpt remain taken togeth assumpt result
peak annual sale dpx-survivac recurr ovarian cancer mln us
see exhibit mln eu see exhibit
believ dpx-survivac ovarian cancer estim conserv preliminari result
suggest dpx-survivac could inde garner market share earlier line therapi
respons rate sustain larger cohort
canada research page
amount us ovca survivin restrict progress high-grad serou penetr treat per treat sale amount wt progress penetr treat per treat sale amount wt progress penetr treat per treat sale revenu imv canada research page
amount eu ovca survivin restrict progress high-grad serou penetr treat per treat sale amount wt progress penetr treat per treat sale amount wt progress penetr treat per treat sale revenu imv imv inc
canada research page
diffus larg b-cell lymphoma dlbcl common type non-hodgkin lymphoma
nhl account approxim case put perspect
estim peopl live nhl us annual incid
approxim new case expect similarli across europ estim
mln peopl live nhl estim annual incid approxim
approxim dlbcl patient cure use standard chemotherapi includ
monoclon antibodi rituximab cyclophosphamid doxorubicin vincristin
prednison r-chop howev dlbcl patient develop relaps refractori
diseas cure standard r-chop therapi indic need
effect therapi patient subset
order deriv sale estim dpx-survivac dlbcl assum dpx-survivac
util follow therapeut line similar ovarian cancer model
commerci sale us eu
us assum current preval nhl case assum
dlbcl grow y/i assum dlbcl patient express survivin dpx-
survivac five peptid combin provid coverag across popul assum
respons rate first line adjuv therapi thu assum patient progress
line furthermor assum line patient progress line
assum product launch penetr assumpt increasingli aggress
respect line start
per patient year dpx-survivac irrespect treatment durat
line
eu assum higher annual nhl preval assum discount
price per patient year penetr us market taken togeth
assumpt result peak annual sale dpx-survivac dlbcl bln see
canada research page
exhibit dpx-survivac dlbcl across us eu
amount nhl survivin restrict progress penetr treat per treat sale amount dlbcl progress penetr treat per treat sale amount nhl survivin restrict progress penetr treat per treat sale amount dlbcl progress penetr treat per treat sale revenu imv imv inc
canada research page
imv clinic stage biopharmaceut compani platform technolog applic
multipl indic imv lead clinic candid dpx-survivac current evalu
combin therapeut ovarian cancer dlbcl soon survivin
express cancer believ appropri valuat methodolog captur
inher valu imv multipl clinic endeavor probabl adjust net
present valu sum part analysi larg driven target indic
assum market penetr indic imv current evalu dpx
applic number indic current attribut valu imv lead
formul dpx-survivac ovarian cancer dlbcl compani gener
preliminari evid anti-tumor activ
illustr current account dpx-survivac us eu sale use
line recurr survivin express ovarian cancer therapi assum dpx-
survivac gain fda ema regulatori approv launch model
sale assum margin sale discount back util
discount rate arriv aggreg dpx-survivac npv ovarian cancer
probabl adjust npv valu account likelihood dpx-survivac clinic
success base current phase result present date notabl assum
probabl success discount condit probabl phase oncolog asset
progress phase ii howev premium condit probabl approv
believ bullish probabl assumpt warrant due preliminari anti-tumor
efficaci demonstr date imv rel compet therapeut class
fact model fraction commerci potenti asset negat ex-u
ex-eu rest world sale valuat result per share valu
similar ovarian cancer current account dpx-survivac us eu sale use
dlbcl therapi assum dpx-survivac gain fda ema regulatori approv
launch model sale assum margin sale
discount back util discount rate arriv aggreg dpx-survivac npv
dlbcl unlik ovarian cancer probabl adjust npv valu account
date extrem preliminari result expect elabor earli
valuat result per share valu
us mm except per share discount dpx-survivac us dpx-survivac eu discount aggreg fd ovca per share canada research page
exhibit valuat dpx-survivac dlbcl
initi imv outperform recommend per share target
round base probabl adjust net present valu sum-of-the-
part model remaind target valuat detail per share cash
alloc account aggreg target earli day imv anti-tumor
efficaci ovarian cancer specif encourag furthermor dpx abil drive
tumor infiltr lymphocyt view broad applic across multipl tumor type
look forward anticip multipl valu creat event futur data readout
dpx-survivac ovarian cancer dlbcl
imv intellectu properti portfolio relat dpx deliveri technolog includ sixteen patent
famili first contain eight patent issu five jurisdict us europ canada
japan australia fifteen famili collect contain thirty-seven patent issu
ten jurisdict us europ canada australia japan india israel singapor china
separ hong kong fifti pend patent applic eleven jurisdict take
account valid european patent imv ip portfolio includ seventy-f patent
patent togeth pend applic allow extend patent protect
depovax-bas composit and/or use thereof approxim year
method prepar use thereof treatment cancer
us mm except per share discount dpx-survivac us eu discount aggreg fd dlbcl per share share target valuat summari imv inc
canada research page
fiscal ye dec except interest expensesresearch admin dev intang -- depreci government tax expens -- -- -- -- net incom averag s/o basic fulli per share basic fulli ye dec except current asset cash equival tax current asset properti equip sharehold equitycurr liabil ap accr due current liabil liabilitiesleas share total sharehold equiti liab share equiti canada research page
fiscal ye dec except activitiesnet adjust amort intang loss share unit dispos op work cap account tax due use op activ issuanc share cap share warrant issuanc stock contribut use fin act activ acq use invest activ fx cash cash equiv -- -chang cash cash equiv begin period equiv end period imv inc
canada research page
mr or serv ceo sinc april mr or bring year experi
biopharmaceut industri compani serv number manag role
join imv mr or spent year medicago recent vice-president busi
develop strateg plan integr part medicago success
includ secur mln non-dilut fund revenu futur mileston
licens agreement govern contract mln deal acquisit
mitsubishi pharma mr or serv second vice-chair vaccin industri
committe biotech canada prior medicago licens
manag univers pari vii-deni diderot one largest scienc medic
univers franc bsc degre biolog master degre manag
univers anger franc
mr labb bring year progress financi leadership role variou industri
prior join imv vice-president cfo leddartech inc experi life scienc
sector includ serv cfo secretari medicago inc complet
privat medicago inc follow acquisit mitsubushi pharma enterpris
valu mln career senior financi offic particip
develop strateg plan financ merger acquisit bln
transact mr labb also director osisko gold royalti ltd agil health inc
hold bachelor degre busi administr licens account universit
laval qubec citi mr labb member ordr de comptabl professionnel agr du
qubec charter profession account canada institut corpor
dr rosu bring year medic pharmaceut experi tenur
imv prior imv recent medic scienc liaison janssen inc respons
implement medic strategi region level previous serv global
medic advisor hematolog novo nordisk activ particip develop
global medic strategi clinic develop plan multipl compound duti
also encompass overse clinic trial plan public earli development-
phase compound well regulatori file support post-approv commit late-
stage candid market product
dr rosu previou experi compani includ berlex celgen novo nordisk
lundbeck gain exposur sever therapeut area includ hematolog
oncolog dr rosu graduat univers medicin pharmaci gr popa
nativ countri romania follow graduat internship practic famili
emerg physician iasi romania five year
mr sheldon bring year experi pharmaceut industri name ceo
year vaccin industri excel award world vaccin congress april
head medicago new ventur formerli presid chief execut offic
medicago inc join medicago inc mr sheldon serv vice presid sale
market shire biolog gener manag rhne merieux canada mr sheldon
also board chairman quebec intern quebec citi region mr sheldon
bachelor degre agricultur scienc universit laval qubec citi bachelor
scienc degre honor biolog scienc univers east anglia norwich
canada research page
imv commerci product revenu asid sporad milestone/subcontract revenu
interest incom payment expect continu accumul loss
oper near-term market dynam turn unfavour result imv loos
access capit public market risk insolv furthermor anticip
imv time time issu equiti rais capit thu investor awar
imv lead develop effort therapeut area believ highli
competit name oncolog number compani clinic advanc
rel imv develop immunotherapi imv target indic competit could
jeopard imv abil penetr specif patient popul would materi impact
valu imv equiti
current imv yet asset reach nda/bla phase regulatori process
note even imv success complet clinic trial lead regulatori file
guarante applic approv
oncolog drug particularli orphan therapeut enjoy degre price
inelast increas scrutini drug cost could impair imv abil command price level
line estim furthermor degre flexibl price dpx-survivac may
depend level efficaci demonstr pivot trial
believ critic differenti aspect imv competitor uniqu
differenti skillset held employe togeth encompass multipl decad
technic know-how respect dpx platform believ imv futur success depend
technic engin expertis key employe loss employe
notori frequent litigi compani imv may becom involv
lawsuit protect enforc patent trade secret could expens time
consum unsuccess neg impact imv share
current imv depend develop manufactur partnership factor
could jeopard partnership may beyond control compani could
neg impact imv develop endeavor abil access api clinic trial
commerci product event could result forecast delay would neg impact
canada research page
note price recent close indic exchang may us disclosur section rate definit
